Dr. Jeffrey R. Jay, M.D
Latest statistics and disclosures from Dr. Jeffrey R. Jay, M.D.'s latest quarterly 13F-HR filing:
- Top 5 stock holdings are Hyperion Therapeutics, FURX, VNDA, OGXI, PTIE. These five stock positions account for 66.20% of Dr. Jeffrey R. Jay, M.D.'s total stock portfolio.
- Added to shares of D Stemline Therapeutics, Hyperion Therapeutics, TRGT, MYGN, CSII, PTIE, ZIOP, NGNM, ONTY, Wright Med Group Inc right 03/01/2019.
- Started new stock positions in CSII, ZIOP, D Stemline Therapeutics, MYGN, Wright Med Group Inc right 03/01/2019, NGNM, AVEO.
- Reduced shares in these stocks: ACAD (-$10.93M), Mei Pharma (-$8.17M), QCOR (-$8.02M), CLSN (-$6.91M), FURX (-$6.05M), AMRN (-$5.12M), VASC, Acelrx Pharmaceuticals, OGXI, RTIX.
- Sold out of its positions in ACAD, ARAY, AFFY, AMRN, CLSN, NPSP, QCOR, Sarepta Therapeutics, VASC, Zogenix.
- As of March 31, 2013, Dr. Jeffrey R. Jay, M.D. has $93.33M in assets under management (AUM). Assets under management dropped from a total value of $107.40M to $93.33M.
- Independent of market fluctuations, Dr. Jeffrey R. Jay, M.D. was a net seller by $48.33M worth of stocks in the most recent quarter.
Dr. Jeffrey R. Jay, M.D. portfolio companies for quarter ending March 2013
| Ticker | Name | Portfolio Weight | Change | Share Count | Price | Last Trade |
|---|---|---|---|---|---|---|
| Hyperion Therapeutics | 24.73 | +15.00% | 893961 | 25.82 | 0.00 | |
| FURX | Furiex Pharmaceuticals | 18.89 | -25.00% | 470240 | 37.48 | 36.00 |
| VNDA | Vanda Pharmaceuticals | 8.97 | -7.00% | 2134829 | 3.92 | 5.47 |
| OGXI | OncoGenex Pharmaceuticals | 7.45 | -25.00% | 613276 | 11.33 | 10.19 |
| PTIE | Pain Therapeutics | 6.17 | +21.00% | 1678906 | 3.43 | 2.79 |
| Acelrx Pharmaceuticals | 5.34 | -36.00% | 966379 | 5.16 | 0.00 | |
| D Horizon Pharma | 4.65 | +9.00% | 1601463 | 2.71 | 0.00 | |
| Biodel | 4.11 | 1350400 | 2.84 | 0.00 | ||
| D Stemline Therapeutics | 3.67 | NEW | 300000 | 11.41 | 0.00 | |
| TRGT | Targacept | 3.49 | +212.00% | 761447 | 4.28 | 5.41 |
| EXAS | EXACT Sciences Corporation | 2.50 | -42.00% | 238000 | 9.81 | 10.58 |
| MYGN | Myriad Genetics | 1.91 | NEW | 70000 | 25.41 | 33.26 |
| CSII | Cardiovascular Systems | 1.87 | NEW | 85000 | 20.48 | 18.70 |
| Mei Pharma | 1.46 | -85.00% | 157661 | 8.63 | 0.00 | |
| ONTY | Oncothyreon | 1.35 | +70.00% | 605774 | 2.08 | 2.06 |
| PTN | Palatin Technologies | 1.29 | -24.00% | 2000000 | 0.60 | 0.64 |
| ZIOP | ZIOPHARM Oncology | 0.79 | NEW | 402500 | 1.83 | 1.75 |
| NGNM | NeoGenomics | 0.65 | NEW | 152920 | 3.94 | 0.00 |
| Wright Med Group Inc right 03/01/2019 | 0.54 | NEW | 200000 | 2.50 | 0.00 | |
| AVEO | AVEO Pharmaceuticals | 0.10 | NEW | 12800 | 7.34 | 2.90 |
| RTIX | RTI Biologics | 0.09 | -95.00% | 22365 | 3.93 | 4.40 |
| AMAG | AMAG Pharmaceuticals | 0.00 | 150 | 26.67 | 25.46 |
Past 13F-HR SEC Filings for Dr. Jeffrey R. Jay, M.D.
- Dr. Jeffrey R. Jay, M.D. 2012 Q4 - filed Feb. 14, 2013
- Dr. Jeffrey R. Jay, M.D. 2012 Q3 - filed Nov. 14, 2012
- Dr. Jeffrey R. Jay, M.D. 2012 Q2 - filed Aug. 14, 2012
- Dr. Jeffrey R. Jay, M.D. 2012 Q1 - filed May 14, 2012
- Dr. Jeffrey R. Jay, M.D. 2011 Q4 - filed Feb. 14, 2012
- Dr. Jeffrey R. Jay, M.D 2011 Q3 - filed Nov. 14, 2011
- Dr. Jeffrey R. Jay, M.D 2011 Q1 - filed May 16, 2011